Mercachem logo voor websites

Update COVID-19:

The COVID-19 situation is currently impacting most of the globe, including Asia, Europe and North America. At all MercachemSyncom sites, we follow the recommendations of the local competent authorities as they are released. We have established a series of contingency measures aimed at reducing risks for our employees, their families and the MercachemSyncom Operations. These measures are proactively being reassessed at regular intervals and adapted as deemed appropriate.

The MercachemSyncom team is united and determined to face the situation with the energy, strength and passion that constitute one of our hallmarks.

 Mercachen 2 Milestone Almirall


In December 2016, Almirall obtained exclusive rights to Mercachem’s cytokine blockers program, such that Mercachem would work to identify and develop novel small-molecule therapeutics for inflammatory skin diseases. With the nomination of a lead compound, Mercachem achieved the second milestone in the medicinal chemistry collaboration program for developing and progressing small-molecule cytokine blockers. Mercachem is also eligible to receive further development milestones.

“This shows the innovative research capabilities of Mercachem to progress challenging targets and chemistries, and also demonstrates the true strength of working in partnerships.” said Eelco Ebbers, co-founder and Managing Director of Mercachem.


Full Press Release

Contact Us